Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

• Main Authors: Jing Ni (Author), Rui Zhou (Author), Xianzhong Cheng (Author), Xia Xu (Author), Wenwen Guo (Author), Xiaoxiang Chen (Author)
• Formato: Livro
• Publicado em: BMC, 2020-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and...